Bristol Myers Squibb 1Q Revenues: $11.9 billion (+5%) 1Q Loss: $11.9 billion (earnings were $2.3 billion 1Q23) Comments: Revenue growth in the quarter primarily driven by Eliquis, Reblozyl and Opdualag, partially offset by Opdivo and Revlimid. Eliquis sales were $3.7 billion in the quarter, up 12%. Reblozyl sales were $354 million, up 88%. Opdualag sales were $206 million, up 71%. Opdivo sales were down 10% to $2.0 billion in the quarter and Revlimid sales were down 5% to $1.7 billion.   Re...